1. Improved Survival of Hepatocellular Carcinoma (HCC) in HIV-Infected Patients with Undetectable HIV RNA Oral Poster Presentation Tuesday, 20 July 2010 Emma Page*, Eugenia Vispo, David E. Kaplan, Luciana Kikuchi, Marina Núñez, Mark Nelson, Pablo Barreiro, Jorge Daruich, Kristen Marks, Rena Fox, Morris Sherman, Massimo Puoti, Norbert Bräu. Liver Cancer in HIV Study Group * Chelsea & Westminster Hospital * Imperial College, London

2. HCC in HIV – HIV RNA Level and Survival: Methods Retrospective Inclusion Criteria: HIV+, HCV Ab, AASLD 2005 n=115 Undetectable: HIV RNA < 400 c/ml 68 (59%) 51.4 63 (93%) 319 49 (72%) Jul ’05 26 (40%) 42 (62%) 3 (4.4%) Detectable: HIV RNA > 400 c/ml 47 (41%) 51.5 43 (92%) 320 36 (77%) May ’03 8 (18%) 21 (45%) 7 (15%) N age Male CD4 HCV date Dx no ETOH Screening CTP: C

3. HCC in HIV – HIV RNA Level and Survival Tumor Characteristics HIV RNA <400 n=68 HIV RNA 400+ n=47 P Hepatic Lesions: Single Tumor52%45%0.52 Median Size Largest Tumor (cm), range 3.5 (0.5 – 18) 5.6 (2.0 – 20) 0.017 AFP Level, Median (ng/mL)2311,5040.045 HCC Therapy HIV RNA <400 n=68 HIV RNA 400+ n=47 P Potentially Curative, n (%) Radiofrequency Ablation Percutaneous Ethanol Injection Surgical Resection Liver Transplantation Effective, Non-Curative, n (%) Chemoembolization Sorafenib No Therapy, n (%) 22(32%) 9 3 8 2 23(34%) 20 3 23 (34%) 9 (19%) 5 4 0 10(21%) 9 1 28 (60%) 0.024 Emma Page for Liver Cancer in HIV Study Group, AIDS 2010, Vienna

4. HCC in HIV – HIV RNA Level and Survival: Survival All Patients No HCC TherapyEffective, Non-Curative Therapy Potentially Curative Therapy Emma Page for Liver Cancer in HIV Study Group, AIDS 2010, Vienna

5. Thank you much for your kind attention Emma Page for Liver Cancer in HIV Study Group, AIDS 2010, Vienna